MedTrace Logo

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

NCT02213289 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-04-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.

Conditions

  • Adenocarcinoma

Interventions

DRUG

Trastuzumab

Trastuzumab

DRUG

ABT-806

ABT-806

DRUG

Bemarituzumab

Bemarituzumab

DRUG

Ramucirumab

Ramucirumab

DRUG

Nivolumab

Nivolumab

DRUG

Standard cytotherapy

FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Daniel Catenacci, MD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-20
Primary Completion
2020-02-01
Completion
2020-08-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02213289 on ClinicalTrials.gov